FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 13, 2026
Annovis Bio, Inc. (ANVS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $28.9 million.
Revenue (TTM)
$0
Net income (TTM)
$-49.52M
-63.7% vs year-ago TTM
Operating cash flow (TTM)
$-43.34M
-75.5% vs year-ago TTM
Free cash flow
—
EPS (TTM)
$-1.79
+5.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
28.36M
+45.5% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANVS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1477845
- Former names
- QR Pharma, Inc. (until Mar 15, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$29.7M | -$26.7M | -$45.0M | -$25.5M | -$14.5M |
| Net income | -$28.9M | -$24.6M | -$56.2M | -$25.3M | -$14.5M |
| Diluted EPS | -$1.40 | -$2.31 | -$6.23 | -$3.10 | -$1.90 |
| Operating cash flow | -$25.6M | -$21.9M | -$40.0M | -$17.3M | -$9.1M |
| Total assets | $21.1M | $13.9M | $10.2M | $36.0M | $46.0M |
| Total liabilities | $4.2M | $4.6M | $18.0M | $7.7M | $1.5M |
| Stockholders' equity | $16.9M | $9.3M | -$7.8M | $28.3M | $44.5M |
| Cash and investments | $19.5M | $10.6M | $5.8M | $28.4M | $45.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Nov 4, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Oct 30, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
All 312 Annovis Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.